2026-01-28
ImmuneCare, a Subsidiary of ImmuneOnco, Files Patent for IMC-015 Bispecific Antibody Differentiated "Fat-Loss & Muscle-Gain" Strategy Poised to Tackle GLP-1-Induced Muscle Loss
Shanghai, China, 28 January 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that its subsidiary, ImmuneCare Biopharmaceuticals (Shanghai) Co.,
View more
2026-01-19
ImmuneCare, a Subsidiary of ImmuneOnco, Successfully Completes Subject Enrollment for First Cohort in MAD Study of IMC-003 for Pulmonary Arterial Hypertension
Shanghai, China, January 19, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that its subsidiary, ImmuneCare Biopharmaceuticals (Shanghai) Co.,
View more
2026-01-12
mmuneOnco Biopharmaceuticals' Timdarpacept (IMM01) Receives NMPA Approval for Clinical Trial in Atherosclerosis
Shanghai, China, January 12, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that the clinical trial application for its self-developed timdarp
View more
